NVCR

SEC source: 0001997032-26-000004 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,422

F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

SEC source: 0001194459-26-000001 · primarydocument.xml · derivative · entry 6

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,517

Underlying: Ordinary Shares · 30,072 shares

Expires 2036-03-03

F6 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

SEC source: 0001194459-26-000001 · primarydocument.xml · derivative · entry 5

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,445

Underlying: Ordinary Shares · 258,445 shares

Expires 2036-03-03

F6 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

SEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 4

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 328,397

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 3

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,727

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 2

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,284

F2 · security: Represents vesting of performance-based restricted stock units.

SEC source: 0001194459-26-000001 · primarydocument.xml · nonDerivative · entry 1

DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

SEC source: 0002039078-26-000004 · primarydocument.xml · nonDerivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,343

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 3

Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 223,477

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $13.31 USD to $13.36 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 3

Leonard Frank X · CIK 0001822879 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,400

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 4

Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 440,208

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 3

Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 447,436

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 2

Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,749

F3 · security: Represents vesting of performance-based restricted stock units.

SEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 2

Leonard Frank X · CIK 0001822879 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,632

F3 · security: Represents vesting of performance-based restricted stock units.

SEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 2

Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 449,846

F2 · security: Represents vesting of performance-based restricted stock units.

SEC source: 0001917165-26-000003 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,328

F1 · security: Represents vesting of performance-based restricted stock units.

SEC source: 0002039078-26-000004 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,751

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 1

Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,757

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.79 USD to $13.91 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001997032-26-000003 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,322

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

SEC source: 0002007766-26-000002 · primarydocument.xml · nonDerivative · entry 1

Leupin Nicolas · CIK 0002007766 · Former Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,079

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,011

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

SEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 426,028

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0002039078-26-000002 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,306

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001997032-26-000001 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,763

F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025.

SEC source: 0001654435-26-000001 · primarydocument.xml · nonDerivative · entry 1

Danziger Asaf · CIK 0001654435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 416,474

F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025.

SEC source: 0001917165-26-000001 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,573

F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025.

SEC source: 0002039078-25-000004 · primarydocument.xml · nonDerivative · entry 2

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,439

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0002048634-25-000004 · primarydocument.xml · nonDerivative · entry 1

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,117

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0002039078-25-000004 · primarydocument.xml · nonDerivative · entry 1

Paravasthu Mukund · CIK 0002039078 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,388

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001822879-25-000006 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,745

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001997032-25-000004 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,762

F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

SEC source: 0001562180-25-006130 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,569

F1 · price: On the transaction date, the reporting person purchased 81,550 shares in multiple trades at prices ranging from $12.02 to $12.47. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 3

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,150

SEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 2

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,150

SEC source: 0001562180-25-005572 · primarydocument.xml · nonDerivative · entry 1

Brackmann Christoph · CIK 0002048634 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,150

SEC source: 0001562180-25-005189 · primarydocument.xml · nonDerivative · entry 1

Puri Michal Nath · CIK 0001997032 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,514

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

SEC source: 0001562180-25-005188 · primarydocument.xml · nonDerivative · entry 1

Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,711

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

SEC source: 0001562180-25-005187 · primarydocument.xml · nonDerivative · entry 1

Danziger Asaf · CIK 0001654435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 416,473

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

SEC source: 0001562180-25-005186 · primarydocument.xml · nonDerivative · entry 1

Cordova Ashley · CIK 0001822014 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,019

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

SEC source: 0001562180-25-005185 · primarydocument.xml · nonDerivative · entry 1

Ben Arye Barak · CIK 0001917165 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,465

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.

SEC source: 0001562180-25-004561 · primarydocument.xml · derivative · entry 2

Stafford Kristin · CIK 0001970438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004561 · primarydocument.xml · nonDerivative · entry 1

Stafford Kristin · CIK 0001970438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,269

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004562 · primarydocument.xml · derivative · entry 2

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004562 · primarydocument.xml · nonDerivative · entry 1

LEUNG GABRIEL · CIK 0001236183 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,444

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004560 · primarydocument.xml · derivative · entry 1

Madden Martin J. · CIK 0001696864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,393

Underlying: Ordinary Shares · 33,393 shares

Expires 2035-06-04

F1 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004559 · primarydocument.xml · derivative · entry 2

HILLEMAN JERYL L · CIK 0001216628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004559 · primarydocument.xml · nonDerivative · entry 1

HILLEMAN JERYL L · CIK 0001216628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,806

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004558 · primarydocument.xml · derivative · entry 2

Ocean Allyson J · CIK 0001967326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · security: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004558 · primarydocument.xml · nonDerivative · entry 1

Ocean Allyson J · CIK 0001967326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,269

F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.

SEC source: 0001562180-25-004557 · primarydocument.xml · derivative · entry 2

Scannell Timothy J · CIK 0001451533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,697

Underlying: Ordinary Shares · 16,697 shares

Expires 2035-06-04

F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.